Pacific Shuanglin Bio-pharmacy Co., Ltd. (SZSE: 000403)
Health Care · Biotechnology · CN
CN¥10.63
-2.48% today · -41.6% 1Y
Pacific Shuanglin Bio-pharmacy Co., Ltd. (SZSE: 000403) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.50B and employs 2,755 people.
Over the last twelve months the share price has lost 41.6%, trading between 8.54 and 18.52.
Tweenvest scores Pacific Shuanglin Bio-pharmacy Co., Ltd. across four factors: quality 75/100, value 72/100, growth 75/100. Its strongest factor is quality.
000403 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.50B
- Revenue (TTM)
- $377.08M
- P/E
- 29.88
- EPS
- 0.36
- Dividend yield
- —
- Beta (5Y)
- 0.45
- 52-week high
- CN¥18.52
- 52-week low
- CN¥8.54
- Avg volume (3M)
- —
- Shares outstanding
- 950.40M
- Employees
- 2,755
- Next earnings
- —
About Pacific Shuanglin Bio-pharmacy Co., Ltd.
Based in Taiyuan, China, Pacific Shuanglin Bio-pharmacy Co., Ltd. operates extensively within the country, focusing on biochemical engineering, the production of pharmaceutical industry equipment, and medical materials. The company's diverse product portfolio includes a range of vital human blood-derived therapies such as serum albumin, various forms of human immunoglobulin (including specific preparations for rabies, hepatitis B, tetanus, and intravenous human immunoglobulin (PH4)). They also manufacture topical remedies like tianqi analgesic cream, musk herd cream, musk bone paste, anti-inflammatory analgesic cream, and dieshangling plasters, alongside general medical gauzes. Beyond current offerings, Pacific Shuanglin is actively engaged in developing advanced biopharmaceutical products, including porcine pulmonary surfactants, shaqifang compounds, a1-protease inhibitors, human coagulation factor VIII products, and human fibrinogens. Furthermore, the company expands its interests to encompass investment, consultation, and technology promotion for pharmaceutical and biotechnology projects. Its broader ventures include real estate development, electronic product information services, and the provision of electricity. The entity adopted its current name, Pacific Shuanglin Bio-pharmacy Co., Ltd., in April 2021, having previously been known as Southern Shuanglin Bio-pharmacy Co., Ltd.
- ISIN
- CNE000000F14
- Founded
- 1993
- Listed since
- Feb 8, 2013
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $263.50 | -0.55% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.55 | +0.28% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $144.90 | -0.83% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.37 | +0.06% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $823.94 | -1.21% |
| argenx SEENXTBR: ARGX | $65.85B | €867.40 | -3.84% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $135.64 | -6.50% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.